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I.

INTRODUCTION

[1]
This paper will examine the issues surrounding the codevelopment of drugs derived from traditional medicines used by
indigenous peoples in Amazonia, with a focus on Peru. In particular, this
paper will explore what national, regional and international legal
structures are in place to protect the interests of indigenous peoples, while
at the same time providing medical benefit to the world. This issue is
explored in the context of Peruvian, U.S., and international treaties –
especially the TRIPS agreement, the Andean Community, sui generis
protections, and the US-Peru Trade Promotion Agreement.
[2]
Commenters have noted that historically, drug development
ventures based on traditional medical knowledge (TMK) from Amazonia
had not been pursued in a manner that was fair and just to the indigenous
peoples who owned this knowledge.1 There are two pragmatic “fairness”
* The author is Dean and Professor of Business, and Professor of Pharmaceutical
Sciences, at Concordia University Wisconsin. He would like to thank Dean Arneson,
Pharm.D, Ph.D. (Professor and Dean of the CUW School of Pharmacy) for providing the
pictures from his trips to Peru, and Professor Kali Murray at Marquette University for
many helpful comments and guidance. This research was supported, in part, by National
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considerations in the U.S.-Peruvian co-development of drugs derived from
indigenous peoples in Amazonia, based on TMK.2 First, any co-venture
should identify the best legal structure(s) that protects the interests of
researchers in both Peru and the United States, and the need to also protect
the interests of indigenous peoples.3
[3]
Second, any co-venture should consider whether international
pharmaceutical patent protection is inherently biased to protect drugs as
defined in western (U.S.) medical practice, versus the traditional and
historically-based practices of indigenous peoples.4 There are potential
problems for intellectual property (IP) protection, since medical treatments
in traditional cultures are typically developed by groups over long periods
Institutes of Health (NIH) grants AI101975, GM118304 and HL112639.
1

See, Manuel Ruiz, Isabel Lapeña, and Susanna E. Clark, The Protection of Traditional
Knowledge in Peru: A Comparative Perspective, 3 WASH. U. GLOB. STUD. L. REV. 755,
760 (2004).

2

See Ley N° 27811 [Law No. 27811], art. 5, Aug. 10, 2002, El Peruano,
http://www.wipo.int/edocs/lexdocs/laws/es/pe/pe011es.pdf, archived at
https://perma.cc/28J9-VW3L (trans. at
http://www.wipo.int/edocs/lexdocs/laws/en/pe/pe011en.pdf, archived at
https://perma.cc/99RJ-GWCM (Peru) (Law Introducing a Protection Regime for the
Collective Knowledge of Indigenous Peoples derived from Biological Resources).

3

See generally, Howard Mann, Intellectual Property Rights, Biodiversity and Indigenous
Knowledge: A Critical Analysis in the Canadian Context, Report Submitted to the
Canadian Working Group on Articles 8(j) of the Convention on Biological Diversity
(Ottawa, 1997) (Analyzing intellectual property rights of Aboriginal people in Canada
with regard to today’s laws, and addressing the correlating barriers and opportunities for
the use of intellectual property rights in relation to indigenous knowledge and resources).

4

See, e.g., Heather A. Sapp, Monopolizing Medicinal Methods: The Debate Over Patent
Rights for Indigenous Peoples, 25 TEMP. J. SCI. TECH. & ENVTL. L. 191, 196 (2006)
(“…[W]estern patent systems appropriately exclude [Traditional Knowledge] from patent
protection.”).
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of time, as opposed to the more rapid discovery by individual researchers
or companies in the pharmaceutical industry. In the former situation, it
may be impossible to patent a medical treatment if it has been “in use” for
many years since prior public use can create novelty or obviousness bars
to patenting.5 Furthermore, most traditional medicines are mixtures of
natural products (i.e., chemical compounds that are “products of nature”),
comprised of two or more active chemical ingredients; whereas, drug
discovery and development in the U.S. focuses on composition of matter
patent protection for single chemical compounds. Additionally, most
pharmaceutical companies will not develop drugs in the U.S., unless they
can obtain composition of matter patent protection on single chemical
compounds.
[4]
Given these differences in how medicines are developed and used
in the U.S. versus Peru, coupled with different views of IP and TMK, what
is the best IP protection and collaborative structure for co-development of
medicines by pharmaceutical researchers in the U.S. and Peru, and
traditional healers (shamans) in Amazonia? This paper explores the legal
and cultural issues surrounding this question, then proposes solutions that
build on existing legal structures and trends in the U.S. and Peru.
[5]
Section I of this paper introduces challenges associated with codevelopment of drugs by researchers, defines key terms and concepts, and
provides an example of one TMK-based medicine used by Amazonian
shamans. Section II presents an attempted drug development initiative
where indigenous rights were ignored. This involved the attempted
patenting in the U.S. of a traditional medicine from Amazonia, ayahuasca.
Section III of this paper explores the various legal structures and treaties in
Peru, the Andean region, and the U.S., as well as international treaties that
5

See Gene Quinn, The Impact of the America Invents Act on the Definition of Prior Art,
IP WATCHDOG (Oct. 3, 2012), http://www.ipwatchdog.com/2012/10/03/the-impact-ofthe-america-invents-act-on-the-definition-of-prior-art/id=28453/,
archived
at
https://perma.cc/6RGD-KTJ7.
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pertain to intellectual property rights (IPR) of indigenous peoples, with
respect to their general traditional knowledge (TK), and TMK in
particular. Section IV builds on this background, and proposes a
collaborative co-development research agreement that could be used by
U.S. and Peruvian researchers who team up to discover and develop new
medical treatments based on TMK. Such collaborations could be a
tremendous new source of medicines.
[6]
As the pipeline of new medicines coming from the U.S.
pharmaceutical industry is dwindling, research and development costs are
increasing and productivity of the industry is decreasing.6 These forces are
converging to create intense market pressures, and perhaps more openness
to explore new solutions to address the world’s medical needs.7 These
solutions will likely include academic researchers in the U.S. (and Europe)
teaming up with researchers in Amazonia, to learn from their indigenous
peoples.8 Together, they can co-develop new medical treatments based on
the TMK possessed by Amazonian shamans; but, this can only work
efficiently and fairly if the interests of the collaborating research teams
and of the indigenous peoples from which the TMK originates, are

6

See Ish Khanna, Drug Discovery in the Pharmaceutical Industry: Productivity
Challenges and Trends, 17 DRUG DISCOVERY TODAY 1055, 1088 (2012), http://ac.elscdn.com/S1359644612001833/1-s2.0-S1359644612001833-main.pdf?_tid=4b6731ea7ede-11e6-ab6500000aab0f01&acdnat=1474340569_16e7ca651037b847bcc9a375343d47de, archived at
https://perma.cc/Y7QN-4ZQG.

7

Id. at 1095-96.

8

See e.g., Carolyn Gregoire, Scientists Put Shamanic Medicine Under the Microscope,
HUFFINGTON POST (Oct. 16, 2015), http://www.huffingtonpost.com/entry/shamanmedicine-autoimmune-disease_us_55f8737be4b0d6492d633c23, archived at
https://perma.cc/K3XP-W3S8.
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considered upfront and with equal weight.9 This paper aims to facilitate
that process.
A. What are Traditional Knowledge (TK) and Traditional
Medical Knowledge (TMK)?
[7]
Traditional knowledge (TK) is defined by the World Intellectual
Property Organization (WIPO) as “knowledge, know-how, skills and
practices that are developed, sustained and passed on from generation to
generation within a community, often forming part of its cultural or
spiritual identity.”10 Negotiations on an international legal instrument,
developed by the WIPO Intergovernmental Committee (IGC), are focused
on developing protections for TK, along with protections for Traditional
Cultural Expressions and Genetic Resources. This paper will focus on
identifying protective strategies for a subset of TK, with a focus on TMK.
[8]
Traditional Environmental Knowledge (TEK) is a subset of TK
and the focus of western scientific fields such as ethnobotany and
ethnomedicine.11 Martha Johnson defined TEK as “…a body of
knowledge built by a group of people through generations, living in close
contact with nature. It includes a system of classification, a set of
empirical observations about the local environment, and a system of selfmanagement that governs resource use.”12 TEK can be distinguished from
9

See id.

10

WORLD INTELLECTUAL PROP. ORG. (WIPO), Traditional Knowledge,
http://www.wipo.int/tk/en/tk/, archived at https://perma.cc/96MH-S43M (last visited
Sept. 21, 2016).

11

Joe McCarter & Michael C. Gavin, Perceptions of the Value of Traditional Ecological
Knowledge to Formal School Curricula: Opportunities and Challenges From Malekula
Island, Vanuatu, 7 J. ETHNOBIOLOGY & ETHNOMEDICINE, no. 38, 2011,
https://ethnobiomed.biomedcentral.com/articles/10.1186/1746-4269-7-38, archived at
https://perma.cc/S8UF-FUQG.
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western science in a number of ways, including that: (a) it is transmitted
via oral tradition, (b) is holistic (versus reductionist), (c) is based on a
view of social and spiritual connections between life forms, (d) views the
natural elements as having a life force (infused with spirit), and (e)
explains natural phenomena based on cumulative and collective
experiences that are regularly validated and revised over time.13 Thus,
while TEK bears some resemblance to western scientific knowledge, it is
also distinct in many ways.14 TEK is especially relevant for this paper,
since it is a source of TMK.
[9]
Traditional medical knowledge (TMK) is a type of TK that centers
specifically on the knowledge of traditional healers in their use of plantbased medicines.15 The World Health Organization (WHO) defines TMK
as “the sum total of the knowledge, skills and practices based on the
theories, beliefs and experiences indigenous to different cultures, whether
explicable or not, used in the maintenance of health, as well as in the
prevention, diagnosis, improvement or treatment of physical and mental
illnesses.”16 This paper focuses on the use and protection of TMK in
12

See Martha Johnson, Research on Traditional Environmental Knowledge: Its
Development and Its Role, in LORE: CAPTURING TRADITIONAL ENVIRONMENTAL
KNOWLEDGE 3, 4 (Martha Johnson ed., 1992).

13

See Fulvio Mazzocchi, Western Science and Traditional Knowledge: Despite Their
Variations, Different Forms of Knowledge Can Learn From Each Other, 7 EUROPEAN
MOLECULAR BIOLOGY ORGANIZATION REPORTS 463, 463–466 (2006).

14

See Graham Dutfield, TRIPS-Related Aspects of Traditional Knowledge, 33 CASE W.
RES. J. INT'L L. 233, 242 (2001).

15

See Ryan Abbott, Documenting Traditional Medical Knowledge, WIPO, 3 (Mar. 2014)
http://www.wipo.int/export/sites/www/tk/en/resources/pdf/medical_tk.pdf, archived at
https://perma.cc/2F3G-55CT citing Fact Sheet No. 134: Traditional Medicine WORLD
HEALTH ORG. (WHO) http://www.who.int/mediacentre/factsheets/2003/fs134/en/,
archived at https://perma.cc/7Q4N-E7Z2.
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Amazonia, with a focus on Peru.
B. TMK as a Source of New Medicines
[10] The pharmaceutical industry benefits greatly from TMK. One
estimate is that of the 119 plant-derived chemicals used in modern
medicine, 74% have similar current uses as the medicinal plant from
which the chemical was identified.17 The market value of plant-derived
medicines was estimated at over $15 billion in 1990, for United States
pharmaceutical sales.18 Amazonia, and Peru in particular, is an especially
rich source of traditional medicines.19 One of the most prominent and
spiritually important traditional medicines to Peruvian shamans is
ayahuasca.20
C. Peruvian TMK – Ayahuasca

16

See WORLD HEALTH ORG. (WHO), GENERAL GUIDELINES FOR METHODOLOGIES ON
RESEARCH
AND
EVALUATION
OF
TRADITIONAL
MEDICINE
(2000),
http://apps.who.int/iris/bitstream/10665/66783/1/WHO_EDM_TRM_2000.1.pdf,
archived at https://perma.cc/4HZY-45KQ.

17

See Norman R. Farnsworth, Screening Plants for New Medicines, in BIODIVERSITY 83,
95 (E. O. Wilson ed., 1988).

18

See Peter Principe, Economics and Medicinal Plants, in MEDICINAL PLANTS: THEIR
ROLE IN HEALTH AND BIODIVERSITY 42, 44 (Timothy R. Tomlinson & Olayiwola
Akerele eds., 1998).

19

See Rainer W. Bussmann & Douglas Sharon, Traditional Medicinal Plant Use in
Northern Peru: Tracking Two Thousand Years of Healing Culture, 2 J. ETHNOBIOLOGY
&
ETHNOMEDICINE,
no.
47,
2006,
http://ethnobiomed.biomedcentral.com/articles/10.1186/1746-4269-2-47, archived at
https://perma.cc/H3E6-GKU8.

20

See id.
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[11] Of particular fame and importance amongst shamans in Peru is the
ayahuasca plant (Banisteripsis caapi),21 of the plant family
Malpighiaceae. Ayahuasca was discovered and introduced to the scientific
community by Harvard biologist and “father of modern ethnobotany,”
Richard Evans Schultes.22 In the native Quechua language of Amazonia,
ayahuasca means “vine of the soul.”23 Ayahuasca is used by indigenous
peoples in religious and healing ceremonies.24 Shamans have used
ayahuasca for centuries to treat various psychiatric disorders, which
indigenous peoples sometime believed were associated with witchcraft.25

Fig. 1. Picture of a live ayahuasca root (left panel), and
a piece of the root sold in a Peruvian market (right panel).26
21

See infra Figure 1.

22

See Richard E. Schultes, The Botanical and Chemical Distribution of Hallucinogens, 9
J. PSYCHEDELIC DRUGS 247, 251 (1977).

23

See Kenneth W. Tupper, The Globalization of Ayahuasca: Harm Reduction or Benefit
Maximization?, 19 INT'L J. DRUG POL'Y 297, 297–303 (2006).

24

See Marlene Dobkin De Ríos, Banisteriopsis in Witchcraft and Healing Activities in
Iquitos, Peru, 24 ECON. BOTANY 296, 296 (1970).

25

See id.

26

E-mail attachment from Dr. Dean Arneson, Pharm.D, Ph.D., Dean of School of
Pharmacy, Concordia University Wisconsin, to author (2013) (on file with author).
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[12] While available for purchase in markets (Fig. 1),27 the use of
ayahuasca is generally restricted to shamans or ayahuasqueros who
possess valuable TMK, since they know best how to prepare it in a way
that is safe and effective.28 The ayahuasca plant (Banisteriopsis caapi)
vine is mixed in defined ratios and manners with plants such as Psychotria
viridis, then boiled.29 Chemicals from both of these plants work
synergistically to produce the desired effect. Specifically, “harmala
alkaloid” molecules (Fig. 2)30 in ayahuasca inhibit an enzyme called
monoamine oxidase (MOA) – preventing the chemical breakdown of the
active chemical present in the Psychotria viridis plant, dimethyltryptamine
(DMT).31 DMT produces the psychoactive effects of this traditional
medicine by altering the activity in brain synapses of the serotonin
receptors (Fig. 2).32

27

See supra Figure 1.

28

See De Ríos, supra note 24, at 296.

29

See id. (stating that the boiled ayahusca infusion is sometimes mixed with additives
like chacruna, a Quechua word describing the plant otherwise known as Psychotria
viridis).

30

See infra Figure 2.

31

See J.C. Callaway et al., Pharmacokinetics of Hoasca Alkaloids in Healthy Humans, 65
J. ETHNOPHARMACOLOGY 243, 244 (1999).

32

See id.; see also Dennis J. McKenna, J.C. Callaway & Charles S. Grob, The Scientific
Investigation of Ayahuasca: A Review of Past and Current Research, 1 HEFFTER REV. OF
PSYCHEDELIC RESEARCH 65, 67 (1998); see infra Figure 2.
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Fig. 2. Active chemical components in ayahuasca teas used by
shamans, with serotonin comparison.33
[13] In cases where shamans develop and administer medical treatments
based on TMK, and scientists later explain the molecular basis for that
medical effect and identify the active chemical components, who is the
inventor? This question, exemplified in the case of ayahuasca, is
complicated.34 While the shamans, as TMK practitioners, knew how these
plants needed to be mixed to achieve the desired effect, scientists
ultimately discovered the molecular reason for needing the mixture.35
Indeed, scientists could extract the active chemical components, mix them
in the correct ratio, and develop this as a drug – taken perhaps as a pill.
Which is the greater discovery? Both are important, and certainly the
shaman’s TMK is a “but for” cause of the scientific (i.e. molecular)
33

See Callaway et al., supra note 31, at 245.

34

See, e.g., Andrea Rinaldi & Pryia Shetty, Traditional Medicine for Modern Times:
Facts
and
Figures,
SCIDEV.NET
(June
6,
2015),
http://www.scidev.net/global/medicine/feature/traditional-medicine-modern-times-factsfigures.html, archived at https://perma.cc/9A3E-BUSS.

35

See generally Bussman & Sharon, supra note 19 (discussing Chiappe and Millones as
the first scientists to study the Shaman’s use of ayahuasca).
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discovery. It seems self-evident that the scientific discovery cannot and
should not proceed to the benefit of others, without first considering the
rights of the indigenous peoples who made the initial discovery.
[14] By using TMK, Amazonian shamans uncovered a
pharmacologically useful and valuable medical treatment from ayahuasca.
This treatment exists only because of specific molecular level interactions.
While these molecules might not be patentable subject matter (as products
of nature)36, combinations of molecules might be considered patentable
subject matter, as composition of matter. Pharmaceutical companies will
typically only develop a drug if composition of matter protection can be
obtained. Thus, co-development of TMK-derived drugs poses a challenge
to the IP community, in terms of how a useful medical treatment can be
patented. It is possible to patent at the level of the plants used, the active
chemical components extracted from the plants, or mixtures of those
active chemical components.
[15] TMK-derived drug development also challenges the international
community to consider whether it is ethically permissible to allow this
type of patenting. Is it right to allow researchers who discover the active
molecular components, used in traditional medicines, to patent and then
profit from their scientific discoveries, without returning benefit to the
shamans? Can they patent them, or are there 35 U.S.C. §102 novelty (prior
art) bars that prevent patenting, since shamans have been treating with
traditional medicines, like ayahuasca, for centuries? These questions are
addressed in Section III. While the scientists who discovered the active
chemical components in ayahuasca made no attempt to patent their
discovery, there was a significant controversy over an attempt to patent the

36

See Richard Seth Gipstein, Note, The Isolation and Purification Exception to the
General Unpatentability of Products of Nature, 4 COLUM. SCI. & TECH. L. REV. 2
(2003).
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ayahuasca plant itself.37 It was after this ayahuasca patent dispute that
significant changes to protect TK and TMK were implemented in Peru.
II. A CASE STUDY IN BIOPROSPECTING OF TMK: LESSONS FROM
AYAHUASCA
[16]
Despite the fact that ayahuasca use was in the shaman’s TMK
toolbox for centuries, Loren Miller obtained a U.S. patent, Plant Patent
No. 5,571 on the ayahuasca plant (Banisteriopsis caapi), which issued on
June 17th, 1986 (Fig. 3).38

Fig. 3. Patent on ayahuasca (Banisteriopsis caapi).39
[17] Recognizing this as an exploitation of TK and TMK, in what is
referred to as “bioprospecting,” David Downes and Glenn Wiser filed a
37

See Leanne M. Fecteau, Note, The Ayahuasca Patent Revocation Questions About
Current U.S. Patent System, 21 B.C. THIRD WORLD L.J. 69, 70 (2001).

38

See U.S. Patent No. Plant 5,751 (filed Nov. 7, 1984); see infra Figure 3.

39

Id.
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request for re-examination.40 Downs and Wiser were with the Center for
International Environmental Law (CIEL), working on behalf of the
Coordinating Body of Indigenous Organizations of the Amazon Basin
(COICA) and the Amazon Coalition, on March 30, 1999.41
[18] The Miller patent had a single claim, for “a new and distinct
(cultivar) of the species Banisteriopsis caapi,” which Miller called “Da
Vine.”42 Downs and Wiser argued this claim was invalid on a number of
legal theories, but especially based on prior art that included publications
and plant specimen sheets, such as one listed as: “Plants of Cultivation:
Banisteriopsis caapi, Accessioned Specimen Sheet, The University of
Michigan Herbarium (mounted Jan. 5, 1981).”43
[19]

Wiser and Downes raised five arguments before the U.S. Patent

40

See David R. Downes & Glenn M. Wiser, Center for Int’l Envtl. Law, Comments on
Improving Identification of Prior Art: Recommendations on Traditional Knowledge
Relating to Biological Diversity Submitted to the United States Patent and Trademark
Office, Aug. 2, 1999, at 15, www.ciel.org/Publications/IdentificationofPriorArt.pdf,
archived at https://perma.cc/R26N-LSRW [hereinafter Comments on Improving
Identifications of Prior Art]; see also David R. Downes & Glenn M. Wiser, The Legal
Elements of the “Ayahuasca” Patent Case, Center For International Environmental Law
(Mar. 30, 1999), http://ciel.org/Publications/ayahuascalegalelements.pdf, archived at
https://perma.cc/F7JE-BFPX [hereinafter Legal Elements].

41

See Downes & Wiser, Legal Elements, supra note 40.

42

U.S. Patent No. Plant 5,751 (filed Nov. 7, 1984).

43

David R. Downes, et al., Request for Reexamination of U.S. Patent No. Plant 5,751
(Mar. 30, 1999), at 1, http://www.ciel.org/wpcontent/uploads/2015/06/ReexaminationofUSPlantPatent5751.pdf, archived at
https://perma.cc/L6JE-N6YV;
Downes & Wiser, Comments on Improving Identifications of Prior Art, supra note 40, at
15.
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and Trademark Office (PTO) as to why the Miller patent was not valid.44
First, they claimed the existence of significant prior art, which should
produce 35 U.S.C. §102 rejections.45 Specifically, they argue that the plant
Miller is patenting is not new and distinct, because it is “well described in
the scientific literature and in the ‘traditional knowledge of indigenous
peoples throughout Amazon.’”46 Banisteriopsis caapi was described in
herbarium specimens, as well as a number of more typical printed
publications that discuss the medicinal and ceremonial use of ayahuasca.47
[20] Second, Wiser and Downes argued that under the U.S. Patent Act
one cannot patent plants if they “[are] found in an uncultivated state,” in
the wild.48 There is a statutory bar in 35 U.S.C. §161 that prevents
patenting of plants found in the wild, and this should prevent patenting of
Miller’s “Da Vine.” While Miller argues that “Da Vine” was only found in
a garden (i.e. in a cultivated state), this was apparently not true.
Banisteriopsis caapi is actually found throughout the Peruvian Amazon
region.49
44

See generally Downes & Wiser, Comments on Improving Identifications of Prior Art,
supra note 40, at 13–16 (discussing arguments against the validity of Miller’s patent).

45

See id. at 4.

46

Daniel S. Sem, Legal, Ethical and Business Consideration in Developing Drugs
Derived from Traditional Medicine, in Conference Report, UNIV. OF APPLIED SCIENCES
UPPER AUSTRIA SCH. OF MGMT. CROSS-CULTURAL BUSINESS CONFERENCE 2016 96, 98
(May 19-20, 2016), https://www.fh-ooe.at/fileadmin/user_upload/fhooe/ueberuns/kongresswesen/2016/ccbc/allgemein/docs/fhooe-ccbc2016-proceedings-final.pdf,
archived at https://perma.cc/AJN8-PSSK.

47

See Downes, et al., supra note 43, at 1–2.

48

Downes & Wiser, Comments on Improving Identifications of Prior Art, supra note 40,
at 13 n. 39.

49

See id. at 13; see also, supra note 35.
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[21] Downes and Wiser then make a third argument – one that has
significant implications, since it also suggests a mechanism by which
indigenous peoples might protect their plant-based TMK.50 They argue
that accession sheets of plants from herbarium collections can be
categorized as prior art within the meaning of 35 U.S.C. §§ 102 and 103.51

Fig. 4. Sample of a herbarium sheet from Cayetano
University in Peru.52
[22] The existence of such herbarium sheets should bar any future
patenting of the plant that was preserved on the sheet.53 While there may
only be a single copy of the herbarium sheet, if it is accessible to the
public, it may be considered prior art. In the same way that “a single
catalogued thesis in one university library [constitutes] sufficient
accessibility to those interested in the art exercising reasonable diligence,”
50

See Downes & Wiser, Comments on Improving Identifications of Prior Art, supra note
40, at 14–15.

51

See id. at 15.

52

See E-mail from author, to Dr. Dean Arneson, Pharm.D, Ph.D., Dean of School of
Pharmacy, Concordia University Wisconsin (2013) (on file with author).

53

See Downes & Wiser, Comments on Improving Identifications of Prior Art, supra note
40, at 15.
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is considered a printed publication, for purposes of a prior art rejection
under 35 U.S.C. §102.54 To serve as prior art, the herbarium sheets must
be accessible and available to persons interested in the subject matter–in
this case medicinal plants associated with the TMK of Amazonian
shamans. If this is true, then one way for indigenous peoples to prevent
patenting of their medicinal plants is to make herbarium sheets containing
dried plant specimens with written entries (e.g. describing the plant, where
collected, date collected), such as that shown in Fig. 4 from the University
of Cayetano in Peru.55
[23] Downs and Wiser make a fourth argument, based more on a sense
of social justice than on patent law.56 They argue that the patent should be
canceled because the plant (ayahuasca) has been used by indigenous
peoples for hundreds of years, long before Miller considered patenting
“Da Vine.”57 Of course, the challenge from a patent perspective is that this
use – part of an oral tradition – may not have been documented in any
printed publication and U.S. patent law does not prevent patenting of
subject matter that was simply “in use” in a foreign country (at least not

54

In re Hall, 781 F.2d 897, 900 (Fed. Cir. 1986) (“…we reject appellant’s legal argument
that a single cataloged thesis in one university library does not constitute sufficient
accessibility to those interested in the art exercising reasonable diligence.”).

55

See supra Figure 4.

56

See generally Downes & Wiser, Comments on Improving Identifications of Prior Art,
supra note 40, at 3, 5–6, 16 (discussing the social implications on the traditional
knowledge of indigenous communities).

57

See id.; see also Glenn Wiser, Center for Int’l Envtl. Law, U.S. Patent and Trademark
Office Reinstates Ayahuasca Patent: Flawed Decision Declares Open Season on
Resources of Indigenous Peoples, (June 25, 2001) at 1, http://www.ciel.org/wpcontent/uploads/2015/06/PTODecisionAnalysis.pdf, archived at https://perma.cc/PY75MJZG.
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before the 2013 America Invents Act [AIA]).58 In an analogous situation,
a U.S. patent for use of turmeric in wound healing (based on Indian TMK)
was issued in 1995.59 This patent was canceled because turmeric had
actually been used for many generations by indigenous peoples in India
for this same purpose, so the invention was not considered novel.60
[24] Finally, Downs and Will argued that the Miller patent should not
be allowed on moral and public policy grounds:
“… issuance of the Patent does not meet the public
policy and morality aspects of the Patent Act, which
preclude awarding a patent on a plant … that is sacred to
indigenous peoples … and revered in their cultures for
many generations … the PTO should not provide patent
protection to a plant based on supposed medicinal
characteristics that are well known in the systems of
traditional knowledge of indigenous peoples … the PTO
may and should decline to award intellectual property
rights where their imposition would violate established
moral, religious and cultural values.”61

58

See infra Section III (E).

59

Use of Turmeric in Wound Healing, U.S. Patent No. 5,401,504 (filed Dec. 28, 1993).

60

Sanjay Kumar, India Wins Battle with USA Over Turmeric Patent, 350 THE LANCET
675, 724 (1997); Use of Turmeric in Wound Healing, U.S. Patent and Trade Office
Reexamination Certificate B1 5,401,504 (Apr. 21, 1998).

61

Detailed Statement in Support of Request for Reexamination of U.S. Plant Patent No.
5,751 from David R. Downs & Glenn Wiser to the Commissioner of Patents and
Trademarks (filed Nov. 7, 1984), http://www.ciel.org/wpcontent/uploads/2015/06/ReexaminationofUSPlantPatent5751.pdf, archived at
https://perma.cc/5XJ9-YQMN [hereinafter Detailed Statement].

17

Richmond Journal of Law & Technology

Volume XXIII, Issue 1

[25] While this moral argument is attractive, there is little support in
U.S. patent law for an argument based on protection of “moral, religious
and cultural values.”62 U.S. patent law has no equivalent to the moral
rights doctrine of copyright law. Although, a PTO Media Advisory
statement63 offers a glimmer of hope for moral grounds arguments –
noting that courts had excluded inventions that are “injurious to the wellbeing, good policy, or good morals of society.”64 Downs and Wiser argue
that patenting plants like ayahuasca, which are used widely in religious
ceremonies as part of indigenous peoples’ TMK, “offends religious and
moral sensibilities” and “wrongly appropriates traditional knowledge of
indigenous and local communities [and] may deprive its creators and
conservators of incentives to preserve, develop and improve upon it.”65
Perhaps because this moral sensibilities argument is not supported by U.S.
patent law and associated legal precedent, the PTO ultimately based its
decision to reject the Miller patent on other arguments presented by
Downs and Wiser.66
[26] After considering the request for reexamination and the various
arguments presented by Downs and Wiser, the PTO responded by

62

Id. at 4.

63

See generally Press Release 98-6, USPTO, Facts on Patenting Life Forms Having a
Relationship to Humans, (April 1, 1998) (on file with author),
http://www.uspto.gov/about-us/news-updates/facts-patenting-life-forms-havingrelationship-humans, archived at https://perma.cc/7MDZ-SSLJ.

64

Tol-O-Matic, Inc. v. Proma Produkt-Und Marketing Gesellschaft m.b.H., 945 F.2d
1546, 1553 (Fed. Cir. 1991) (citing Lowell v. Lewis , Fed. Case No. 8568 (C.C. Mass.
1817)).

65

Downes & Wiser, Detailed Statement, supra note 61, at 24.

66

See infra Section III (E).
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rejecting the Miller patent in a November 3, 1999 office action.67 They
did this in part based on a consideration of the herbarium specimen sheets
as being “printed matter” that could serve as prior art, under §102(b).68
One particular herbarium specimen that was identified as prior art was:
“Plants of Cultivation: Banisteriopsis caapi, The University of Michigan
Herbarium (mounted Jan. 5, 1981).”69 This is significant precedent
because it is the first such consideration of herbarium sheets as prior art.
Thus, herbarium sheets like those in Fig. 4 could be used as a bar to
prevent patenting of plants that are part of TMK, and a potential source of
new drugs.70 This result suggests one mechanism by which countries with
indigenous populations might protect their plant-based TMK – by creating
herbarium collections documenting the plants they use in traditional
medicine. By rejecting the patent based on this narrow view only (i.e.
§102, prior art), the PTO avoided the broader question of rejection based
on public policy and morality grounds, which could potentially be
associated with the Patent Act’s utility requirement, as noted in the Media
Advisory statement.71

67

See Glen M. Wiser, U.S. Patent and Trademark Office Reinstates Ayahuasca Patent,
Flawed Decision Declares Open Season on Resources of Indigenous Peoples CIEL 2
(June 25, 2001).

68

See Ex parte Nehls, No. 2007-1823 (B.P.A.I. Jan. 28, 2008).

69

Downes & Wiser, Detailed Statement, supra note 61, at 1.

70

See generally Glen M. Wiser & David R. Downes, CENTER FOR INTN’L ENVTL. LAW,
Comments on Improving Identification of Prior Art: Recommendations on Traditional
Knowledge Relating to Biological Diversity Submitted to the United States Patent and
Trademark Office, (Aug. 2, 1999), http://www.ciel.org/wpcontent/uploads/2015/03/IdentificationofPriorArt.pdf, archived at https://perma.cc/7P9UQTSN.

71

See Press Release 98-6, USPTO, supra note 63.
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[27] The “Da Vine” patent reexamination teaches three important
lessons. First, one way to prevent biopiracy is to create “printed
documents” that could serve as prior art, and therefore block the patenting
of plant-based TMK. Second, one effective type of “printed document”
that can be used for this purpose are collections of herbarium sheets that
document the plants that are part of shamanic TMK. If indigenous peoples
take this defensive move of creating herbarium sheets as prior art, they
should be aware that this may also prevent them from patenting as well,
either alone or as part of a collaborative drug co-development effort. Prior
art creation is a protective tool that cuts both ways; so, it should be used
with caution. Third, an argument based on the moral and social harm
caused to indigenous peoples, while intuitively attractive, may not carry
weight with the PTO due to lack of supporting legal precedent and
statutory language.

III. LEGAL PROTECTIONS OF TMK FOR DRUG CO-DEVELOPMENT IN
PERU
A. Peruvian, Bolivian and Ecuadoran Law
a. Constitutional Protections in Peru, Bolivia and Ecuador
[28] While Peru does not directly protect indigenous rights, Chapter II,
Article 68 of the Peruvian Constitution provides a related protection: “The
State is obliged to promote the conservation of biological diversity, and
protected natural areas.”72 So, to the extent that TMK is associated with
biological diversity (i.e. plant-based medicines), Peru has some relevant
constitutional protection. In contrast, Bolivia and Ecuador’s more recent
constitutions have more explicit protections for indigenous people’s TK,
72

Constitución Política Del Perú [C.P.] art. 68.
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with several articles of the Bolivian Constitution excerpted below:
Article 42: The promotion of traditional medicine shall
incorporate a registry of natural medicines and their active
substances, as well as the protection of the associated
knowledge as intellectual, historical and cultural property,
and as patrimony of indigenous nations and peoples.
Article 100. The State shall protect knowledge by
means of a registry of intellectual property that safeguards
the intangible rights of indigenous nations and peoples…
Article 304. Indigenous autonomies have the following
competences: … safeguard and register collective
intellectual rights related to knowledge on genetic
resources, traditional medicine and germplasm …73
[29] The Bolivian Constitution is relatively new, having been approved
only in 2009; and, it is a result of the 2005 election of Evo Morales, an
Aymara coca peasant who fought for the rights of indigenous peoples.74
Given its origins in a political movement focused on indigenous peoples, it
can be viewed as a model for national protection of TK IP rights. While
Bolivia and Ecuador are unique in having these protections at the
constitutional level, their Constitutions may have value as persuasive legal
authority for other Andean Community countries like Peru, and for any
country that seeks to protect the TK and TMK of its indigenous peoples.
b. Sui Generis Protections in Peru: Law No. 27811
[30]

While Peru does not protect TMK at the constitutional level, it

73

See GRAIN, The Struggle Against IPR in the Andes, SEEDLING, July 12, 2009, at 21.

74

Id. at 20.
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does protect TK and TMK in its national legislation.75 In particular, Peru
passed Law No. 27811 in 2002, introducing a Protective Regime for the
Collective Knowledge of Indigenous People Derived from Natural
Resources. The objectives of Law No. 27811 are stated in Article 5:
(a) To promote respect for and the protection,
preservation, wider application and development of the
collective knowledge of indigenous peoples;
(b) To promote the fair and equitable distribution of the
benefits derived from the use of that collective knowledge;
(c) To promote the use of the knowledge for the benefit
of the indigenous peoples and mankind in general;
(d) To ensure that the use of the knowledge takes place
with the prior informed consent of the indigenous peoples;
(e) To promote the strengthening and development of
the potential of the indigenous peoples and of the
machinery traditionally used by them to share and
distribute collectively generated benefits under the terms of
this regime;
(f) To avoid situations where patents are granted for
inventions made or developed on the basis of collective
knowledge of the indigenous peoples of Peru without any
account being taken of that knowledge as prior art in the
75

See Ley N° 27811 [Law N° 27811], Ley que Establece el Régimen de Protección de
los Conocimientos Colectivos de los Pueblos Indígenas Vinculados a los Recursos
Biológicos [Law Introducing a Protection Regime for the Collective Knowledge of
Indigenous Peoples Derived from Biological Resources], Aug. 10, 2002, EL PERUANO, at
227953–54 (Peru).
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examination of the novelty and inventiveness of the said
inventions.76
[31] Noteworthy is the emphasis on informed consent and equitable
sharing of benefits, along with specific protections for patents and other
protections.77
[32] The “Protective Regime for the Collective Knowledge of
Indigenous People Derived from Natural Resources” (Law No. 27811)
goes beyond the general objectives outlined in Article 5, to describe in
detail how TK (and TMK) is to be protected. It explains the key
considerations when intellectual property is to be licensed from
indigenous peoples. In particular, if a third party is going to commercialize
traditional knowledge (Article 7) it requires outside parties to sign license
agreements to “ensure due reward for said access and … equitable
distribution of the benefits … .”78 A percentage of benefits (at least 10%)
must go to the Fund for the Development of Indigenous Peoples (Article
8).79 Thus, it ensures that the indigenous owners of TMK are duly
rewarded, and benefits obtained in any drug co-development efforts are
shared equitably. Furthermore, it explicitly points out that protected
knowledge does not belong to individuals, but rather to groups of
indigenous peoples.80 That is, knowledge and discovery is “collective”
(Article 10), in contrast to the individualistic approach that underlies U.S.

76

Id. at art. 5.

77

See id at art. 5(d),(e).

78

Id. at art. 7.

79

See Ley N° 27811 [Law N° 27811], supra note 75 at art. 8.

80

See id. at art. 10
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patent law and, more generally, U.S. culture.81
[33] The law goes on to describe how national registers of TK and
TMK are to be created. Title VI describes the formation of registers of
collective knowledge, with Article 15 explicitly creating three types of
registers: (a) Local Registers of Collective Knowledge of Indigenous
Peoples, (b) Private National Registers of Collective Knowledge of
Indigenous Peoples, and (c) Public National Registers of Collective
Knowledge of Indigenous Peoples.82 Article 20 describes what type of
information must be included in the registration of the TK and TMK into
these registers.83
[34] These three registers each serve unique and important purposes.
The first, The Local Registers, are managed by indigenous peoples with
assistance of the National Institute for the Protection of Competition and
Intellectual Property (INDECOPI).84 They serve the local needs of
indigenous peoples, to enable sharing of their TMK with each other, and
to provide a high level of access to and control of information by the local
community. The second, the Private National Registers, are kept
confidential, and contain what could be viewed as trade secrets.85 These
trade secrets could be licensed to third parties, if desired. The third, the
Public National Registers, could serve the alternative purpose of providing
prior art that will prevent the patenting of TMK by other countries (e.g.

81

Id.

82

Id. at art. 15.

83

See id. at art. 20.

84

See Ley N° 27811 [Law No. 27811], supra note 75 at art. 24.

85

See id. at art. 18.
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via 35 U.S.C. §102 in the U.S.).86 Indeed, Article 23 specifically states
that “INDECOPI shall send the information entered in the Public National
Register to the main patent offices of the world in order that it may be
treated as prior art in the examination of the novelty and inventiveness of
patent applications.”87 Thus, Peru has made a very explicit defensive move
to prevent the patenting of its TK and TMK; this was a valuable lesson
from the ayahuasca case above (section II), and is now institutionalized in
national policy.88 Interestingly, the recent passage of the U.S. AIA has
obviated some of the need for this defensive strategy, since prior use (even
if no printed publication exists) is now considered a bar in considering
novelty or non-obviousness (inventiveness).89 This is discussed in greater
detail in section III(E).
[35] The Private National Register contains TK and TMK trade secrets
which could be of significant value to the world as a source of new
medicines. To enable dissemination of this TMK, if desired, indigenous
peoples can license their TMK to third parties, such as pharmaceutical
companies. But, they must register the license according to the Article 26
“Compulsory written form for license contracts” requirements.90 The
contents of this contract are designed to protect the intellectual property
rights (IPRs) of the indigenous owner, and are specified in Article 27:
(c) A statement of the compensation that the indigenous
86

See id. at art. 23.

87

Id.

88

See discussion supra Section II.

89

See infra Section III(E).

90

See Ley N° 27811 [Law No. 27811], supra note 75 at art. 26.
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peoples receive for the use of their collective knowledge;
such compensation shall include an initial monetary or
other equivalent payment for its sustainable development,
and a percentage … of the gross sales resulting from the
marketing of the goods developed …;
(d) The provision of sufficient information on the
purposes, risks and implications of the said activity … ;
(e) The obligation on the licensee to inform the licensor
periodically … of progress in the research on and
industrialization and marketing of the goods developed …;
(f) The obligation on the licensee to contribute to the
improvement of the ability of the indigenous peoples to
make use of the collective knowledge …91
[36] A “toolkit” to assist in compliance with this licensing process is
available from WIPO.92 The required elements of a TMK license contract
are designed to protect the interests and rights of the indigenous owners,
and should be considered in the preparation of any drug co-development
research agreements between Peruvian researchers and their U.S. or other
foreign collaborators.93
B. U.S.-Peru Trade Promotion Agreement (TPA)
91

Id. at art. 27.

92

See WORLD INTELLECTUAL PROP. ORG. (WIPO), Traditional Knowledge
Documentation Toolkit (2012),
http://www.wipo.int/export/sites/www/tk/en/resources/pdf/tk_toolkit_draft.pdf, archived
at https://perma.cc/85DN-5V4S (last visited Nov. 11, 2013).

93

See id. at 22.
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[37] Beyond the scope of TRIPS (Trade Related Aspect of Intellectual
Property) standards, the U.S.–with WTO (World Trade Organization)
enforcement (as described in Section III(D))94–has also pursued bi-lateral
trade agreements with individual countries, typically seeking higher IPR
standards.95 Such bi-lateral agreements often lead to less protection for
TK, so are often conceded to by developing countries only because of the
other benefits they receive. While the end result may provide broader
benefits to the government that signs, such bi-lateral agreements – and the
associated concessions that are made – can anger indigenous groups and
their representatives. This appears to have been the case in Peru as well.
[38] The U.S. and Peru signed the Trade Promotion Agreement (TPA)
in 2006.96 Within the TPA is a benefit to the so-called Andean Community
countries (Bolivia, Peru, Ecuador, Columbia)97, via the Andean Trade
Protection Act (ATPA). This benefit to the Andean Community countries
required that IPRs be protected adequately under WTO, as specified by
TRIPS standards. Peru signed various amendments on Dec. 21st, 2008, to
permit compliance with the TPA with the U.S. These changes generally
strengthened IP, and weakened protections of TK, TMK and biodiversity,

94

See infra Section III(D).

95

See Free Trade Agreements, OFF. OF THE U.S. TRADE REPRESENTATIVE,
http://www.ustr.gov/trade-agreements/free-trade-agreements, archived at
https://perma.cc/BQ9K-8X67 (last visited Sept. 9, 2016).

96

See Final Text United States – Peru Trade Promotion Agreement, OFF. OF THE U.S.
TRADE REPRESENTATIVE, (Apr. 12, 2006), http://www.ustr.gov/trade-agreements/freetrade-agreements/peru-tpa/final-text, archived at https://perma.cc/GH7G-VSNX.

97

See COMMUNIDAD ANDINA,
http://www.comunidadandina.org/Seccion.aspx?id=189&tipo=QU&title=somoscomunidad-andina, archived at https://perma.cc/B2U5-PASZ (last visited Sept. 9, 2016)
(describing the countries benefitting).
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against patenting and bioprospecting.98 At about this same time (Dec. 31st,
2008), likely in reaction to signing of the TPA, the local government in
Cusco released an executive order to “protect traditional knowledge,
practices and innovations of local communities.”99 This protection
included a requirement to use “informed consent, compulsory benefit
sharing and the right of communities to say no to bioprospecting.” 100
Furthermore, any bioprospecting requires a permit, and the government
will monitor such activities to protect the interests of local communities.101
These protections of TK and TMK are in keeping with the Article 5
priorities outlined in Peru’s sui generis protection (described above, in
section III(A)(b)), and are consistent with the Constitutional IPR
protections provided in Bolivia (described in section III(A)(a)).102
[39] Importantly, the TPA with the U.S. included an “Understanding
Regarding Biodiversity and Traditional Knowledge,” in an effort to
provide some protection of TK and TMK.103 The Understanding stated:
The Parties recognize the importance of traditional
knowledge … to cultural, economic, and social
development. The Parties recognize the importance of the
following: (1) obtaining informed consent from the
98

See GRAIN, The Struggle Against IPR in the Andes, supra note 73 at 18.

99

Id.

100

Id. (emphasis added).

101

Id.

102

See supra Sections III(A)(a)-(b); see GRAIN, The Struggle Against IPR in the Andes,
supra note 73, at 17.

103

U.S.-Peru Trade Promotion Agreement: Potential Economy-wide and Selected
Sectoral Effects. Inv. No. TA-2104-20, USITC Pub. 3855 at 6-12 (June 1, 2006).
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appropriate authority prior to accessing genetic resources
under the control of such authority; (2) equitably sharing
the benefits arising from the use of traditional knowledge
and genetic resources; and (3) promoting quality patent
examination to ensure the conditions of patentability are
satisfied …
Each Party shall endeavor to seek ways to share
information that may have a bearing on the patentability of
inventions based on traditional knowledge or genetic
resources by providing:
(a) publicly accessible databases that contain relevant
information; and
(b) an opportunity to cite, in writing, to the appropriate
examining authority prior art that may have a bearing on
patentability. 104
[40] While the Understanding does not oblige each country or its
nationals to undertake specific actions in relationship to TMK, the
Understanding’s basic recognition of TMK sets an important precedent.
Previously, the U.S. had felt that TK and TMK protections should be
secured through the WIPO; but, the Andean Community countries –
operating as a regional group with enhanced political bargaining power –
were successful in getting this Understanding added to the TPA.105 This
Understanding can hopefully serve as a starting point and model for how
104

Understanding Regarding Biodiversity and Traditional Knowledge, U.S.-Peru, (April
12, 2006),
http://www.ustr.gov/sites/default/files/uploads/agreements/fta/peru/asset_upload_file719
_9535.pdf, archived at https://perma.cc/66P2-X795.

105

Id.
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the IPRs of indigenous peoples can and should be protected in trade
agreements, as well as in other contexts. Noteworthy is its emphasis on
informed consent, sharing of benefits, assistance in obtaining patents, and
use of TK databases.106 These are also key elements in regional
regulations for the Andean Community, described in the next section.
C. Regional Protections: The Andean Community Intellectual
Property Regime
[41] The Andean Community is an agreement that was signed in 1969,
and currently includes Peru, Bolivia, Ecuador and Columbia (Venezuela
withdrew in 2006 when Peru signed the Free Trade Agreement (FTA)
with the U.S.).107 The Andean Community has generated a number of
supranational institutions, including the “Commission of national
executives, a General Secretariat of regional administrators, and a
Tribunal of Justice (the ATJ or the Andean Tribunal).”108
[42] This Andean Community has had its most significant successes in
the realm of protecting intellectual property (96% of rulings relate to IP),
developing supranational laws called “Decisions” to regulate patents,
trademarks and copyrights.109 Andean IP Decisions are adopted at the

106

See id.

107

See GRAIN, The Struggle Against IPR in the Andes, supra note 73 at 17,19.

108

Laurence R. Helfer & Karen J. Alter, The Influence of the Andean Intellectual
Property Regime on Access to Medicines in Latin America, in BALANCING WEALTH AND
HEALTH: GLOBAL ADMINISTRATIVE LAW AND THE BATTLE OVER INTELLECTUAL
PROPERTY AND ACCESS TO MEDICINES IN LATIN AMERICA 1 (Rochelle Dreyfuss & César
Rodríguez-Garavito, eds., 2013).

109

See id. at 2.
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national level by member states. Then they are interpreted in national
courts, administrative agencies in member states, or by the ATJ.110
[43] The Andean governments have used the political clout afforded to
them, via participation in the Andean Community, to facilitate
incorporation of normally optional TRIPS “flexibilities” as obligatory
features of Andean law.111 To this end, “member states made a collective
decision to capitalize on TRIPS’ flexibilities as a way to promote public
health,” and to resist pressure from stronger international forces, like
pharmaceutical companies from the United States.112 In effect,
membership in the Andean Community gives strength to individual
countries, by virtue of their banding together, to enforce what are
sometimes optional and yet advantageous TRIPS features. This enhanced
bargaining power plays a central role in securing TK and TMK protections
for indigenous peoples, as in the U.S.-Peru TPA agreement discussed
above.
[44] As a complement to regional treaties, local laws can provide
additional protections – as Cusco had pursued in parallel with Peru’s
signing of the U.S.-Peru TPA.113 As discussed above, the signing of this
international agreement (the TPA) by Peru was closely linked to
complementary and compensatory initiatives at the local (Cusco) and
regional (Andean Community) levels, which ultimately led to stronger TK
and TMK protections. Accordingly, any drug co-development initiative
with Peru must recognize the complementary TMK protections that have
been created at the local, national, regional, and international levels.
110

See id. at 1.

111

See id. at 4.

112

Id.

113

See GRAIN, The Struggle Against IPR in the Andes, supra note 73 at 17,18.
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D. International Treaties: Role of UN, TRIPS, WTO and
WIPO
[45] International protections for indigenous IPRs go beyond bi-lateral
agreements like the TPA. Although they are not a focus of this paper,
since regional and bi-lateral agreements are usually compliant with and
more specific than the international treaties. Nonetheless, a brief overview
of key international treaties and agreements will be presented. One such
agreement is the United Nations (UN) Convention on Biological
Diversity.114 This agreement protects TK, which is related to biological
diversity, and encourages sharing of the benefits of that knowledge.
Article 8(j) of the Convention provides that each Party shall:
[s]ubject to its national legislation, respect, preserve
and maintain knowledge, innovations and practices of
indigenous and local communities embodying traditional
lifestyles relevant for the conservation and sustainable use
of biological diversity and promote their wider application
with the approval and involvement of the holders of such
knowledge, innovations and practices and encourage the
equitable sharing of the benefits arising from the utilization
of such knowledge, innovations and practices.115
[46] The emphasis on preservation of TK is noteworthy, promoting the
wider application of the TK and the sharing of benefits obtained through
the use of the TK. More broadly, the Convention on Biological Diversity
focuses on protecting biological diversity in the context of other goals
such as the need for medicines.116 The treaty has importance for
114

See Convention on Biological Diversity, June 5, 1992, 1760 U.N.T.S. 79, 31 I.L.M.
818 (1992), http://www.cbd.int/doc/legal/cbd-en.pdf, archived at https://perma.cc/4BVBMTFW.

115

Id. at 6.
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bioprospecting, as well as collaborative research between countries
involving natural products and TMK.
[47] The Trade Related Aspects of IP (TRIPS) agreement is an
international treaty that seeks to harmonize IP laws between member
countries while still honoring and respecting national laws and
sovereignty.117 TRIPS is the most extensive multinational agreement on IP
and covers patents, trademarks, copyrights, and trade secrets.118 But
TRIPS has not provided significant protections for TMK (beyond certain
“flexibilities”), since the interests of developing nations must often yield
to those of more powerful developed countries (and opt-out of the
“flexibilities”).119 The World Trade Organization (WTO) requires TRIPS
ratification for membership. So it is not uncommon for developing
countries to make undesired concessions regarding IP rights (defined in
TRIPS), in order to secure the trade benefits they desire.120 Counteracting
this pressure is the strength that regional alliances, like the Andean
Community, provide so that TMK protections can be obtained (e.g.
making TRIPS “flexibilities” mandatory in member countries).121
116

See id. at 24.

117

See generally, Agreement on Trade-Related Aspects of Intellectual Property Rights,
Annex 1C, Apr. 15, 1994, LEGAL INSTRUMENTS-RESULTS OF THE URUGUAY ROUND,
1869 U.N.T.S. 299, 33 I.L.M. 81 (1994) (supporting need for multilateral framework
between member countries).

118

See Overview: The TRIPS Agreement, WORLD TRADE ORG.,
https://www.wto.org/english/tratop_e/trips_e/intel2_e.htm, archived at
https://perma.cc/9ZST-3HXV (last visited Sept. 9, 2016).

119

See J.H. Reichman, The TRIPS Agreement Comes of Age: Conflict or Cooperation
with the Developing Countries?, 32 CASE W. RES. J. INT’L. L. 441, 452 (2000).

120

See id.
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See WORLD INTELLECTUAL PROP. ORG. (WIPO), Advice on Flexibilities under the

33

Richmond Journal of Law & Technology

Volume XXIII, Issue 1

[48] Both Peru and the United States are members of TRIPS.
Membership in TRIPS requires compliance with earlier IP treaties and
conventions, including WIPO, the Paris Convention for the Protection of
Industrial Property (Paris Convention),122 and the Berne Convention for
the Protection of Literary and Artistic Works (Berne Convention).123
While TRIPS provides the underlying IP principals, enforcement typically
occurs within member states and disputes are handled by the World Trade
Organization (WTO).124 Since any IPR agreement or treaty developed by
or between Peru and the U.S. must be compliant with TRIPS, the
agreements and treaties with greatest impact on drug co-development
between researchers in Peru and the U.S. are the bi-lateral, regional and
national agreements discussed in sections III A-C.
E. Changes in U.S. Patent Law: the America Invents Act
(AIA)
[49] What effect do the America Invents Act (AIA) changes to U.S.
patent law have on protections of indigenous IPR?125 Under the old 35
TRIPS Agreement, http://www.wipo.int/ipdevelopment/en/legislative_assistance/advice_trips.html, archived at
https://perma.cc/DE85-UJEE (last visited Aug. 30, 2016).
122

See Paris Convention for the Protection of Industrial Property, Mar. 20, 1883, as last
revised July 14, 1967, 21 U.S.T. 1583, 828 U.N.T.S. 311 (applying international treaty to
industrial intellectual property).

123

See Berne Convention for the Protection of Literary and Artistic Works, Sept. 9, 1886,
as last revised July 24, 1971, 25 U.S.T. 1341, 828 U.N.T.S. 221 (international agreement
governing copyright law).

124

See e.g.,Overview: the TRIPS Agreement, supra note 118.

125

See generally Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284
(2011) (modernizing the United States Patent Law system).
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U.S.C. §102, if TMK was “in use” for hundreds of years by shamans in
Peru but never recorded in a printed publication, then there would be no
prior art bar to patenting in the U.S. This would seem to enable biopiracy
of TMK in an undesirable way. Prior to March 16th, 2013 (when the AIA
went into effect), U.S. patent law did not recognize TK and TMK as prior
art if it was only “in use” in a foreign country.126 Indeed, the Patent Act of
1952 would have permitted patenting of an invention based on long-held
TMK (as long as it was undocumented) based on the previous version of
35 U.S.C. §102 (key elements underlined):
A person shall be entitled to a patent unless (a) the invention was known or used by others in this
country, or patented or described in a printed publication in
this or a foreign country, before the invention thereof by
the applicant for patent, or
(b) the invention was patented or described in a printed
publication in this or a foreign country or in public use or
on sale in this country, more than one year prior to the date
of the application for patent in the United States.127
[50] According to the plain language of the statute, while an invention
may have been used in the country of origin (e.g. Peru), 35 U.S.C. §102
will only prevent patenting of inventions that were in use in the U.S. or
described in a printed publication anywhere.128 Thus, when the University
of Mississippi Medical Center tried to patent turmeric for healing wounds,

126

See 35 U.S.C. § 102(a), (b) (2006) (emphasis added).

127

Id. (emphasis added).

128

See id. (emphasis added).
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they were not prevented from patenting simply because turmeric was
widely used for that purpose in India.129 Rather, what led to the patent
being revoked was the appearance of this use of turmeric in printed
publications.130 Likewise, even though ayahuasca had been used for
centuries by Amazonian shamans (i.e. been “in use”), this did not produce
a 35 U.S.C. §102 prior art rejection (see section II). Rather, the rejection
of the Miller patent on ayahuasca was based on the presence of herbarium
sheets that described the ayahuasca plant.131 Indeed, this is a significant
reason why countries like Peru are documenting the plants associated with
their TMK in registries and using herbarium sheets. One of the objectives
of Peru’s sui generis protections (section III(A)(b)) is to ensuring that
foreign bioprospectors are barred from patenting due to the existence of
this prior art.132 But the situation has changed under AIA, where the new
language of 35 U.S.C. §102 is:
(a) A person shall be entitled to a patent unless:
(1) the claimed invention was patented, described in a
printed publication, or in public use, on sale, or otherwise
available to the public before the effective filing date of the
claimed invention;133
[51]

Notably, now 35 U.S.C. §102 considers “public use … or

129

See supra note 59.

130

See supra note 60.

131

See Leanne M. Fecteau, The Ayahuasca Patent Revocation: Raising Questions About
Current U.S. Patent Policy, 21 B.C. THIRD WORLD L. J. 69, 86 (2001).

132

See id. at 73-74.

133

35 U.S.C. §102(a)(1).
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otherwise available” anywhere (in foreign countries and in the U.S.) as
creating a prior art bar to patenting.134 Thus, under the AIA, the need for
countries to maintain registries and herbarium sheets of plants used in
TMK is lessened, as long as they have other means to establish that the
plant and/or TMK had been “in use … or otherwise available.”135 This is
a significant step forward in the prevention of biopiracy, and the
protection of TK and TMK.

IV. MODEL FOR U.S.-PERU COLLABORATIVE DRUG DEVELOPMENT
A. Building on Current IPR Protections for TMK in Peru
a. Key Elements of TMK Protections to Include in
Research
Agreements
Involving
Indigenous
Communities
[52] Constitutional protections of TMK in Peru are limited to
“conservation of biological diversity,” which includes plant-based
medicines.136 Bolivia, a member of the Andean Community along with
Peru, has constitutional protections (see section III(A)(a)) that go further
to explicitly ensure “promotion of traditional medicine” by mandating a
“registry of natural medicines and of their curative properties … as well as
the protection of their knowledge as intellectual … property … of nations

134

Id.

135

Id.

136

See Ley N° 27811 [Law No. 27811], supra note 75 at art. 2(e) (explaining the
protections created by the Peruvian government for collective knowledge of indigenous
peoples in regard to biological resources).

37

Richmond Journal of Law & Technology

Volume XXIII, Issue 1

and indigenous peoples.”137 This theme of protecting TMK in registries
and protecting it as the IP of indigenous peoples, is also manifested in
Peru’s sui generis protections (see section III(A(b))).
[53] Peruvian sui generis protections emphasize creation of databases
of TMK, both public (as a defense against foreign patents) and private (as
a source of licensable trade secrets). Other elements of the sui generis
protections include: (a) promotion of respect, preservation, and wider
application of TMK, (b) promotion of the use of TMK to benefit the
“indigenous peoples and mankind in general,” (c) freedom to license TMK
(with state oversight; to be registered using the WIPO “toolkit”), (d)
release of TMK only with informed consent of the indigenous owners,
based on full disclosure of risks and benefits, (e) equitable sharing of
benefits derived from the use of TMK (including >10% for the Fund for
Development of Indigenous People), and (f) a desire to prevent patenting
of indigenous peoples’ TMK by others.138 These elements and priorities
should be addressed in any collaborative research agreement between
research scientists in Peru and foreign collaborators seeking to co-develop
drugs derived from TMK. Significantly, all of these elements fall under
the broader umbrella of the U.S.-Peru TPA (e.g. informed consent;
equitable sharing of benefits). So, there is a strong foundation for
137

PLURINATIONAL STATE OF BOLIVIA [CONSTITUTION] 2009, Ch. V, art. 43 (Bol.),
https://www.constituteproject.org/constitution/Bolivia_2009.pdf, archived at
https://perma.cc/A9YV-8AP5.

138

See WORLD INTELLECTUAL PROP. ORG. (WIPO), Comparative Summary of Existing
National SUI GENERIS Measures and Laws for the Protection of Traditional
Knowledge, Intergovernmental Committee on Intellectual Property and Genetic
Resources, Traditional Knowledge and Folklore, Fifth Session, WIPO Doc.
WIPO/GRTKF/IC/5/INF/4
http://www.wipo.int/meetings/en/doc_details.jsp?doc_id=17394, archived at
https://perma.cc/D7HC-DJY8 (June 20, 2003).
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including them in collaborative agreements between U.S. and Peruvian
researchers.139
b. Defensive Strategy to Protect TMK - Creation of Public
Databases of TMK as Prior Art
[54] One of the key elements in the Bolivian Constitutional protections
and the Peruvian sui generis protections is the creation of public databases
of TMK. The stated purpose of these databases is, in part, to create prior
art that prevents others from patenting – without permission – the TMK
that belongs to indigenous peoples.140 The need for and value of such
databases is illustrated within the ayahuasca patent dispute described in
section II. While post AIA changes in U.S. patent law lessened the need
for such databases, they still provide a clear demonstration of what TMK
was “in use or otherwise available.” This serves the stated goal of
providing a strong defense against uninvited and undesired foreign
patents, like the Miller “Da Vine” patent. Such patents could exploit the
TMK of indigenous peoples, without equitable sharing of the benefits
derived from that TMK and without informed consent.
[55] It is important to point out that this defensive use of databases as
prior art can have undesired consequences if the indigenous peoples ever
want to patent their own TMK. A key element of the indigenous peoples’
TMK protections (sections III(A)(b) and IV(A)(a)) was a desire to benefit
“indigenous peoples and mankind in general” and to permit – with
informed consent – licensing of TMK-based discoveries in a codevelopment initiative.141 But, pharmaceutical companies will not develop
139

See Peru Trade Promotion Agreement, OFFICE OF THE U.S. TRADE REPRESENTATIVE
https://ustr.gov/trade-agreements/free-trade-agreements/peru-tpa, archived at
https://perma.cc/AW2U-RUYC (last visited Sep. 9, 2016).

140

See Ley N° 27811 [Law No. 27811], supra note 75 at art 42.

141

See supra note 138.

39

Richmond Journal of Law & Technology

Volume XXIII, Issue 1

a drug if they cannot obtain composition of matter patent protection.
Therefore, the inability to patent TMK-derived medicines – or active
substances derived from them – prevents any co-development of drugs.
[56] The most likely patentable subject matter in a drug codevelopment collaboration, since the plant cannot be patented (i.e. as
TMK, it has already been “in use”), are the extracted chemical substances
– or combinations thereof. For example, the ayahuasca plant could not
have been patented under AIA, even if there were no “printed documents”
describing it, since it was already “in use” by shamans. But, the active
ingredients shown in Fig. 2, mixing in the ratios needed to obtain clinical
effect, might have been patentable as composition of matter (ignoring for
now any potential § 101 issues because they are “products of nature”).142
In this regard, the registry suggested in the Bolivian Constitution seems to
anticipate the patenting of active substances (like those in Fig. 2) since it
suggests adding “active substances” to the registry.143 This would enlarge
the prior art shield beyond plants, to include the active components
contained in the plants.
[57] While the inclusion of active chemical substances in national
registries might prevent undesirable patenting by foreign bioprospectors, it
would also prevent desired patenting by Amazonian researchers seeking to
develop or co-develop drugs derived from TMK. This is unfortunate, since
there may be situations where an Amazonian research scientist may want
to co-develop a drug derived from TMK, but now will not be able to do
so. The irony of pharmaceutical development is that no matter how noble
one’s intentions are (e.g. to “benefit mankind”), a strong patent position is
needed so that a company financing the drug development can at least

142

See supra Figure 2.

143

See id.
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recoup its significant investment, often estimated to be in excess of $1
billion.144 How can the stated goal of using TMK to benefit mankind be
achieved, if there is no way to finance the clinical trials that are required
as part of drug co-development? This should be considered when Andean
countries decide to pursue registries as a source of prior art; and, it is a
reason to consider keeping chemical structures of active substances in
private rather than public registries.
c. Trade Secrets – Private Databases of Licensable TMK
[58] The above dilemma is largely solved by using private rather than
public databases of TMK, so that the ability to patent is not lost. For this
reason, and in light of the recent passage of AIA, the private database
should be considered the preferred strategy for protecting the IPR of
indigenous peoples. It is preferred because it leaves open the option to
license their TMK-based IP if and when it is desired, as part of a license
agreement. Such an agreement would of course only be executed with
informed consent and the promise of equitable sharing of benefits.
Although, given that TMK is typically already “in use,” it is questionable
whether – under AIA – it will ever be possible to patent TMK-based
treatments again. But, combinations of active chemical substances, like
those in Fig. 2, may still be patentable; so, that type of information should
be kept private, if indigenous peoples may ever want to patent and/or
license this valuable TMK-derived knowledge.145 It is these active
chemical substances, and strategic combinations thereof, that may be the
only patentable subject matter based on TMK. It is this IP that is most
likely to be the topic of drug co-development projects. And, it is in
144

Drug Developers Are Aggressively Changing the Way They Do R&D, TUFTS CENTER
FOR THE STUDY OF DRUG DEV. (Jan. 5, 2011),
http://csdd.tufts.edu/news/complete_story/pr_outlook_2011, archived at
https://perma.cc/55GK-T5BA.

145

See supra Figure 2.
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enabling these drug co-development projects, eventually involving a
pharmaceutical company that demands composition of matter patent
protection, that the lofty goal of benefiting mankind with TMK can be best
achieved.
d. Strategies to Obtain Composition of Matter Patent
Protection for TMK-derived Drugs
[59] Given the stated desire to benefit the world with TMK, and to – in
some cases – license TMK, there may be times when indigenous peoples,
in collaboration with academic researchers in Peru and abroad, would
want to patent TMK-related inventions, including active substances.146 Is
it possible that the active chemical substances extracted from these plants
– the “drugs” – may be patented as composition of matter (e.g. see Fig.
2)? Naturally occurring chemicals (aka “natural products”) are not
patentable subject matter under 35 U.S.C § 101 if those chemicals are
considered “products of nature.”147 Thus, the answer to this question is, or
was, thought to be no. In general natural products are not thought to be
patentable, unless there is some unique manmade combination of natural
products that is useful in an unanticipated way; and, that combination may
be patentable as composition of matter.148
[60]
146

But, the definition of a “product of nature” may be changing in a

This is an example situation.

147

See Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2116
(2013).

148

See e.g., U.S. Patent No. 7,915,265 B2 (filed Feb. 15, 2006); see also U.S. Patent No.
8,067,433 B2 (filed Nov. 8, 2006); Alice Yuen-Ting Wong & Albert Wai-Kit Chan,
Myriad and Its Implications for Patent Protection of Isolated Natural Products in the
United States, CHINESE
MEDICINE, http://cmjournal.biomedcentral.com/articles/10.1186/1749-8546-9-17,
archived at https://perma.cc/K3VL-4SGX (last visited Sep. 7, 2016).
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way that could open the door to patenting natural products. While an early
case decided by Justice Learned Hand allowed patenting of adrenalin149, a
purified natural product with clinical value, there has not been subsequent
case law to support patenting of natural products simply because they have
been purified.150 This may change, as the U.S. Supreme Court recently
clarified what molecules fall under the “product of nature” exclusion, in
Ass’n for Molecular Biology v. Myriad.151 In this case, Myriad identified
mutated genes (BRCA1 and BRCA2) associated with breast cancer, and
sought to patent this for use as a breast cancer diagnostic.152 The issue is
whether purified naturally occurring deoxyribonucleic acid (DNA)
segments are patentable subject matter, or whether they are excluded as a
product of nature under 35 U.S.C. § 101. Justice Thomas, speaking for the
majority, held that purified DNA was naturally occurring, and therefore
could not become “patent eligible under § 101 simply because they have
been isolated.”153 In contrast, complementary DNA (cDNA) that was
synthesized in the laboratory based on that same DNA sequence was not
considered naturally occurring, so was not excluded as patentable subject
matter; and, therefore, was not considered a product of nature.154 This is
because cDNA is prepared synthetically in the laboratory, and because it
differs from naturally occurring genomic DNA (gDNA) in that it has
noncoding DNA segments (called “introns”) removed, making it distinct
149

See Parke-Davis & Co. v. H. K. Mulford & Co., 189 F. 95., 114 (S.D.N.Y. 1911); see
also Michael D. Davis, The Patenting of Products of Nature, 21 RUTGERS COMPUTER &
TECH. L. J. 293, 326 (1995).

150

See id. at 324.

151

See supra note 147 at 2111.

152

See id at 2113.

153

Id. at 2120.

154

See id.
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from gDNA.155
[61] Myriad teaches that naturally occurring molecules like gDNA (and
by analogy, the ayahuasca active substances in Fig. 2) cannot be patented,
because they are simply purified products of nature. But, if the chemical
substance that is a product of nature is synthesized in a laboratory, and
modified in a routine manner that makes it distinct from its naturally
occurring form, then the molecule is no longer excluded as patentable
subject matter.156 By analogy, one would only need to synthesize and
make routine modifications to the molecules shown in Fig. 2, to be able
avoid the product of nature exclusion. This is a significant change in IP
law surrounding natural products, and may increase the interest of
pharmaceutical companies in the pursuit of such molecules as drugs.
[62] It remains to be seen whether the post-Myriad broadened definition
of “product of nature” will extend to natural products, like the active
chemical substances from ayahuasca (Fig. 2); and, if it does, what will be
the nature of the routine modifications (if any) that are needed. It is
possible that copies of plant-derived molecules, which are synthesized in
the laboratory by chemists, will be considered patentable as composition
of matter under 35 U.S.C. § 101, just as the manmade cDNA copy of
gDNA was found to be patentable in Myriad. It might be argued that the
cDNA molecule is more than simply a manmade copy of the naturally
occurring gDNA molecule, because it has been modified by removal of
introns.157 But, intron removal is a trivial and routine change that is
155

Id. at 2119.

156

See supra note 147 at 2111.

157

See Jason Rantanen, Myriad: Isolated DNA out, cDNA in, PATENTLYO (June 13,
2013), http://patentlyo.com/patent/2013/06/myriad-isolated-dna-out-cdna-in.html,
archived at https://perma.cc/3AZD-BQLW (discussing the outcome of Ass’n for
Molecular Pathology v. Myriad, 133 S. Ct. 2107, 2118 (2013)).
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inspired by what nature does anyhow (introns are removed in making
mRNA).158 It cannot be considered a novel or inventive modification to
the naturally occurring gDNA molecule; although, admittedly, novelty and
inventiveness do not have direct bearing on this § 101 question. Myriad
seems to indicate that one can patent a synthetic copy of a naturally
occurring molecule, if a routine modification is made.159 The key point is
that the molecule does not occur in nature.160 Applying this new test to
other natural products, like the active substances in Fig. 2, there are a
number of foreseeable routine chemical changes that would make the
molecule chemically distinct. A non-exclusive list of possibilities is
provided here:
a) Synthesize chemical variants that have isotopic substitutions, such
as replacing hydrogen atoms with deuterium atoms. This is a
commonly used chemical substitution in drug design.161
b) Convert the basic amine to HCl or other salts. This is also a routine
change to the naturally occurring molecules, and often has utility
for increasing drug bioavailability.162
158

See Z. Peter Sawicki et al., Patenting Biologicals: Myriad Issues and Options in the
Wake of Myriad, BENCH & BAR (Sept. 9, 2013),
http://mnbenchbar.com/2013/09/patenting-biologicals/, archived at
https://perma.cc/GR3J-8PBT.
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See supra note 147 at 2112, 2117 (indicating that a small modification to naturally
occurring DNA would likely qualify as a patentable product).
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Id. at 2116.
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See, e.g., Kristin C. Buteau, Deuterated Drugs: Unexpectedly Nonobvious?, 10 J.
HIGH TECH. L. 22, 26̀–27 (2009); Amanda Yarnel, Heavy-Hydrogen Drugs Turn Heads,
Again: Firms Seek to Improve Drug Candidates by Selective Deuterium Substitution,
CHEM. & ENG’G NEWS (June 22, 2009), http://cen.acs.org/articles/87/i25/HeavyHydrogen-Drugs-Turn-Heads.html, archived at https://perma.cc/NSX4-7CRN.
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c) Make a simple chemical modification, such as acetylation of
amines or alcohols (e.g. with acetic anhydride).163 This type of
modification is what led to drugs like aspirin (acetylated salicylic
acid, from willow tree bark) and heroin (acetylated morphine, from
opium).164
[63] All of the above chemical modifications are routinely used in drug
development, so do not represent novel techniques or changes. But, they
are analogous to and at least as novel as the changes made and techniques
used in going from gDNA or mRNA to cDNA.165 The latter techniques are
performed so routinely that scientists can purchase kits to perform the
production of cDNA from mRNA.166 Thus, it seems that Myriad has
162

See, e.g., Patrick Makary, Principles of Salt Formation, 2 U.K. J. PHARMACEUTICAL &
BIOSCIENCES 4, 1, 3 (2014),
http://www.ukjpb.com/pdf/UKJPB_SuperAdmin_49_49_1411846931.pdf, archived at
https://perma.cc/9CXQ-BHVY .
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See C.R.A. Wright, On the Action of Organic Acids and their Anhydrides on the
Natural Alkaloids, 27 J. CHEM. SOC’Y. 1031, 1032 (1874),
http://pubs.rsc.org/en/content/articlepdf/1874/js/js8742701031, archived at
https://perma.cc/ECR9-V8UC.
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See id; see also U.N. OFFICE ON DRUGS & CRIME, History of Heroin, 5 BULL. ON
NARCOTICS 3, 3 (1953), https://www.unodc.org/unodc/en/data-andanalysis/bulletin/bulletin_1953-01-01_2_page004.html, archived at
https://perma.cc/S5SP-3FSE; BAYER, Felix Hoffmann, http://www.bayer.com/en/FelixHoffmann.aspx, archived at https://perma.cc/HF2J-8JL4 (last visited Sep. 8, 2016).
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See cDNA Production, DAVIDSON COLL. DEPT. OF BIOLOGY,
http://www.bio.davidson.edu/genomics/method/cDNAproduction.html, archived at
https://perma.cc/4PZE-F428 (last visited Sep. 8, 2016).
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See e.g., THERMO FISHER SCIENTIFIC, http://www.thermofisher.com/us/en/home/lifescience/pcr/reverse-transcription/cdna-synthesis-kits.html, archived at
https://perma.cc/FKX6-FYBQ (last visited Sep. 8, 2016).
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opened the door to patenting natural products, after small and even routine
chemical structure changes are made.
[64] If natural products (after routine chemical alteration) can be
patented as composition of matter, this would increase the pharmaceutical
industry’s interest in pursuing natural products as drugs. This would open
the door to more patenting of drugs derived from TMK in co-development
initiatives. This could lead to significant revenue generation (to be shared
equitably with indigenous peoples) and to medical benefits for the rest of
the world.
[65] Even if individual plant-derived molecules (after modification)
cannot be patented as easily as just described, combinations like those
shown in Fig. 2 could be patentable.167 Indeed, combinations of active
substances are central to how many traditional medicines, like ayahuasca,
work (see section II). This is a distinguishing feature of traditional
medicines relative to western medicine.168 Only the shaman, based on
TMK, knows which combinations of plants will produce the desired
therapeutic effect. Then, the chemist can build on this TMK to identify
which combinations of purified active chemical substances extracted from
those plants are needed to reproduce these clinical effects. This
combination, discoverable only through a collaborative co-development
effort between indigenous peoples and scientific researchers, could then be
patented.169
[66]
167

In summary, indigenous peoples should consider the value of

See supra Figure 2.
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E. Chan, M. Tan, J. Xin, S. Sudarsanam & D.E. Johnson, Interactions Between
Traditional Chinese Medicines and Western Therapeutics, 13 CURRENT OPINION DRUG
DISCOVERY & DEVEL. 50, 52 (2010); see supra Section II.

169

Id. at 63.

47

Richmond Journal of Law & Technology

Volume XXIII, Issue 1

composition of matter patent protection, if they hope to reap the full
benefit of their TMK for themselves and the world. Recent developments
in U.S. patent law suggest new strategies to obtain composition of matter
protection to increase the value of indigenous peoples’ TMK to a potential
drug co-development partner from the pharmaceutical industry.
e. Proposed Structure for a Drug Co-Development
Research Agreement
[67] In the interest of transparency and ensuring that the interests of all
parties are considered, it is advisable that drug co-development projects
between Peruvian and U.S. researchers execute a research agreement
when working with indigenous peoples. Such an agreement should build
upon the above legal protections for TMK (section IV(A)(a)), and be
consistent with regional and international laws. A sample agreement is
provided below:170
(SAMPLE) TMK-BASED DRUG CO-DEVELOPMENT RESEARCH
AGREEMENT
[68] This research and drug co-development agreement (“Agreement”)
is made by and among the following collaborating parties (“Parties”):
Indigenous Peoples Representative (“Party 1”), Peruvian Research Team
Representative (“Party 2”), and U.S. Research Team Representative
(“Party 3”).
DEFINITIONS
[69] “TMK” means traditional medical knowledge: “knowledge, knowhow, skills and practices that are developed, sustained and passed on from
170

This sample agreement was created for purposes of this article.

48

Richmond Journal of Law & Technology

Volume XXIII, Issue 1

generation to generation within a community, often forming part of its
cultural or spiritual identity.”171
[70] “INDECOPI” means National Institute for the Protection of
Competition and Intellectual Property: an organization that manages the
Local, National and Public Registers of Collective Knowledge of
Indigenous Peoples.172
[71] “TPA” means The U.S.-Peru Trade Promotion Agreement, the
agreement between the U.S. and Peru that governs trade, but also includes
the “Understanding Regarding Biodiversity and Traditional
Knowledge.”173
[72] “Indigenous Peoples” means “aboriginal peoples holding rights
that existed prior to the formation of the Peruvian State, maintaining a
culture of their own, occupying a specific territorial area and recognizing
themselves as such. These include peoples in voluntary isolation or with
which contact has not been made, and also rural and native
communities.”174
[73] “Informed Consent” means authorization given under this
protection regime, by the representative organization of the indigenous
peoples possessing collective knowledge and in accordance with
provisions recognized by them, for the conduct of a particular activity that
entails access to and use of the said collective knowledge, subject to the
provision of sufficient information on the purposes, risks or implications
171

See supra note 16.

172

See Ley N° 27811 [Law No. 27811], supra note 75 at art. 20.

173

See supra note 96.

174

See Ley N° 27811 [Law No. 27811], supra note 75 at art. 2(a).
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of the said activity, including any uses that might be made of the
knowledge, and where applicable on its value.175
[74]

“CDA” means confidential disclosure agreement.

PROVISIONS
[75] WHEREAS, the Parties share a common interest in developing
drugs derived from TMK;
[76] WHEREAS, the Parties share a desire to see TMK and associated
intellectual property rights (IPRs) protected, yet also benefiting the world;
[77] WHEREAS, the Parties agree to equitably share financial and
other benefits that could result from this collaboration;
[78] WHEREAS, the Parties agree to show mutual respect for each
other’s governing laws, customs and values;
[79] WHEREAS, the Parties agree that TMK is owned by Indigenous
Peoples, and any development and patenting of drugs derived from TMK
will only occur with permission that is be granted by Party 1, after being
fully informed of all relevant risks and benefits via Informed Consent;
[80] WHEREAS, Parties 1 and 2 agree to collaboratively pursue
studies directed to identifying the active chemical component(s) derived
from TMK-based plants, which are responsible for desirable medical
effects;
[81] WHEREAS, the Parties agree to negotiate in good faith any
license agreements for TMK and TMK-derived patents, including
composition of matter patents on active chemical substances;
175

Id. at art. 2(c).
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[82] NOW, IT IS THEREFORE RESOLVED, in consideration of
the forgoing, that the parties hereby agree to the following:
[83]

1. Purpose and Scope
The Parties recognize that Amazonian TMK is a rich source of
useful medical treatments that have been collectively developed over
many years, and is owned by the Indigenous Peoples which Party 1
represents. Parties are mutually committed to the promotion of respect,
preservation and wider application of TMK, as well as the use of TMK to
benefit Indigenous Peoples, and mankind in general. Such benefits include
the development and dissemination of new and better medical treatments.
Benefits may also be financial, based on revenue generated from sales
drugs and/or licensing of IP based on development of TMK-based
medicines. Such development is only to be pursued according to the other
sections of this agreement, which emphasis equitable sharing of benefits,
and Informed Consent (Appendix A) from Party 1, before developing
TMK-derived drugs.
The research and drug co-development team shall engage in
activities that include biological demonstration of safety and efficacy of
TMK-derived treatments, including plant extracts that are prepared by
Party 1. Activities performed by Parties 2 and 3 may also include
purification and chemical characterization of the active chemical
components present in TMK-derived treatments. This may be followed by
chemical synthesis of these active chemical components, and
demonstration of their biological safety and efficacy, alone and in
combinations. Parties 2 and 3 agree to keep Party1 informed of significant
developments in these studies, and to seek the Informed Consent
(Appendix A) of Party 1 before filing patent applications on composition
of matter identified in these studies. Likewise, Parties 2 and 3 agree to
enter these chemical structures into Peru’s National Registries for TK. If a
decision is made to patent the composition of matter, submission will only
be made to the private registry (until the patent publishes). If Party 1
decides to keep the chemical structure information as a trade secret,
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Parties 2 and 3 agree to honor this request, subject to §2 of this agreement.
[84]

2. Decision-making
Party 1 agrees to develop governance procedures that ensure they
are representing the broader interests of the Indigenous Peoples that own
the TMK which is the topic of this research and drug co-development
collaboration. Party 1 has the sole power to decide if chemical structures
of active substances, derived from plant extracts, are to be: (a) kept as
trade secrets, (b) the subject of a patent application, or (c) entered in the
National Public Registry of Collective Knowledge of Indigenous Peoples.
Party 1 agrees to not unreasonably withhold permission to patent; and, if
both Parties 2 and 3 wish to file a patent application, but Party 1 refuses,
Parties 2 and 3 may appeal the decision to an appellate body that has
previously been chosen by the Indigenous People who Party 1 represents.
Other project decisions, which do not directly relate to IPRs, will be made
by majority vote of the three representatives.
[85]

3. Confidential Information
Parties agree to sign a CDA (Appendix B) to protect all
confidential information that is shared or developed in this collaboration.
Such information may include TMK-related trade secrets of Party 1,
including those that are kept in the National Private Register of Collective
Knowledge of Indigenous Peoples. Parties agree to not publicly disclose
chemical structures that are identified during this collaborative codevelopment initiative, without unanimous agreement by all three
representatives. Likewise, Parties 2 and 3 agree to not publicly disclose
trade secrets that have been revealed to them by Party 1, unless Party 1
grants permission to do so.
[86]

4. Intellectual Property (IP)
Parties 2 and 3 agree that all TMK-related trade secrets that predate this agreement, including those that were previously entered into the
National Private Registry of Collective Knowledge of Indigenous Peoples,
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are property of Party 1. Such trade secrets will be revealed and/or licensed
at the discretion of Part 1. Parties 2 and 3 will not patent any TMKderived invention without first obtaining permission from Party 1, and this
permission is to be granted only after Party 1 has signed the Informed
Consent document in Appendix A that outlines all significant risks and
benefits.
The IP that is most likely to result from this collaborative codevelopment initiative includes chemical structures of active substances
that are purified from plant extracts of TMK-based therapies. These
chemical structures will be protected via composition of matter patents or
trade secrets or, at the discretion of Party 1, publicly released via the
Public National Register of Collective Knowledge of Indigenous Peoples,
in order to create prior art that prevents patenting by other parties (subject
to § 3 of this agreement). Parties will work with INDECOPI to enter
TMK-derived information into the National Registers of Collective
Knowledge of Indigenous Peoples, including chemical structures.
[87]

5. Licensing of TMK and TMK-derived Intellectual Property
Since Parties share an interest in benefiting the world based on
TMK-derived therapies, and associated discoveries, and since drug
development is extremely expensive, it may become necessary to license
IP to an external partner. Such an external partner would typically be a
pharmaceutical or biotechnology company that has the resources and
experience needed to develop drugs that result from this collaboration.
Such arrangements typically require that the composition of matter patent
protecting the drug lead molecule be licensed to them; and, it is expected
that the pharmaceutical partner and Parties would negotiate a revenue
sharing arrangement that could include upfront financial payments,
payments upon achievement of certain milestone events (e.g. completion
of different phases of clinical trials), and royalties on net or gross profits
from drug sales, once the drug is approved by appropriate regulatory
agencies, such as the Food and Drug Administration in the U.S.
Parties agree to negotiate in good faith an agreement that equitably
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shares benefits between all three groups, and will be defined in detail in
the license agreement (Appendix C). Such an agreement might include an
equal sharing of revenues between all three groups, although other
arrangements could be negotiated. In negotiating terms, Parties agree to
consider and honor existing legal structures, such as those associated with
the TPA, the Andean Community, and the sui generis protections in Peru
(esp. Law No. 27811).176 Accordingly, Parties agree that the license
agreement will be prepared, executed and properly recorded using the
WIPO “toolkit”177. Any license agreement will ensure equitable sharing of
benefits derived from the use of TMK, including >10% of revenues
provided to the Fund for Development of Indigenous People, before
distribution to the three groups that comprise the Parties.178 Such an
agreement will only be executed after Party 1 has been made aware, via
Informed Consent (Appendix A), of all the risks and benefits associated
with pursuit of the license agreement (Appendix C). Any license
agreement that is executed, even those which are categorized as
“exclusive,” will provide an exception for the Indigenous People that
Party 1 represents, to ensure that they will be able to continue to use their
TMK as they had before the license agreement was executed.
[88] Appendices: (A) Informed consent form, (B) Confidential
disclosure agreement (CDA), (C) Draft license agreement.

V. CONCLUSION
176

See id.

177

See WIPO Toolkit, supra note 92 .

178

See Ley N° 27811 [Law No. 27811], supra note 75 at art. 8.
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[89] The TMK underlying medical treatments used by indigenous
peoples has great value to their communities and may also have great
untapped value for the rest of the world. The goal of the collaborative drug
development projects described herein, involving researchers in the U.S.
and Peru, is to extend the benefits of TMK to the rest of the world, while
respecting the IPR of the indigenous peoples from whom TMK-based
discoveries may be derived. Of particular importance is ensuring equitable
sharing of any future benefits of drug co-development successes with the
indigenous peoples, and making sure all decisions are made based on
informed consent that fully discloses all material risks and benefits.
[90] A model example of a TMK-based medicine is ayahuasca (Fig.
1).179 For ayahuasca to work effectively, the shaman mixes two or more
plants and prepares a tea – a type of plant extraction. Subsequent scientific
research has established why it is necessary to mix these plants, based on
chemical substances that have been extracted and identified from each
(Fig. 2).180 While the researchers who identified these active chemical
substances did not pursue a composition of matter patent on them, such a
strategy could have been taken. If it had, it should only have been pursued
with the informed consent of the indigenous peoples who owned this
TMK-based IP; and, there should be equitable sharing of future benefits.
The example of the Miller patent on the ayahuasca plant (Fig. 3) illustrates
an unsavory effort to bypass this process, which led to public outcry and
the subsequent creation of laws and procedures to ensure protection of
Peru’s IPRs.181
[91] Future drug co-development initiatives should build on these
lessons from ayahuasca, to ensure protection of IPR via compliance with
179

See supra Figure 1.

180

See supra Figure 2.

181

See supra Figure 3.
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national, regional and international laws and treaties, including those
embodied in Peru’s sui generis protections (Law No. 27811), the Andean
Community, and the U.S.-Peru TPA. With these constraints and
guidelines, research collaborations between U.S. researchers, Peruvian
researchers, and indigenous communities can proceed to co-develop
TMK-derived drugs. To guide this process, a draft drug co-development
agreement has been provided in this paper (section IV). Central to this
agreement is a focus on identifying active chemical components from
plant extracts and patenting them as composition of matter. This focus is a
pragmatic requirement, since pharmaceutical companies who may license
these patents for further co-development will only make a significant
financial investment if they have the strong protection that composition of
matter (not method of use) patents provide. This co-development process
has the potential to extend the benefits of TMK to the rest of the world,
which is a shared goal of all parties involved.
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